Literature DB >> 20882278

In vivo ¹⁸F-FDG tumour uptake measurements in small animals using Cerenkov radiation.

Federico Boschi1, Laura Calderan, Daniela D'Ambrosio, Mario Marengo, Alberto Fenzi, Riccardo Calandrino, Andrea Sbarbati, Antonello E Spinelli.   

Abstract

PURPOSE: 2-[(18)F]Fluoro-2-deoxy-D-glucose ((18)F-FDG) is a widely used PET radiotracer for the in vivo diagnosis of several diseases such as tumours. The positrons emitted by (18)F-FDG, travelling into tissues faster than the speed of light in the same medium, are responsible for Cerenkov radiation (CR) emission which is prevalently in the visible range. The purpose of this study is to show that CR escaping from tumour tissues of small living animals injected with (18)F-FDG can be detected with optical imaging (OI) techniques using a commercial optical instrument equipped with charge-coupled detectors (CCD).
METHODS: The theory behind the Cerenkov light emission and the source depth measurements using CR is first presented. Mice injected with (18)F-FDG or saline solution underwent dynamic OI acquisition and a comparison between images was performed. Multispectral analysis of the radiation was used to estimate the depth of the source of Cerenkov light. Small animal PET images were also acquired in order to compare the (18)F-FDG bio-distribution measured using OI and PET scanner.
RESULTS: Cerenkov in vivo whole-body images of tumour-bearing mice and the measurements of the emission spectrum (560-660 nm range) are presented. Brain, kidneys and tumour were identified as a source of visible light in the animal body: the tissue time-activity curves reflected the physiological accumulation of (18)F-FDG in these organs. The identification is confirmed by the comparison between CR and (18)F-FDG images.
CONCLUSION: These results will allow the use of conventional OI devices for the in vivo study of glucose metabolism in cancer and the assessment, for example, of anti-cancer drugs. Moreover, this demonstrates that (18)F-FDG can be employed as it is a bimodal tracer for PET and OI techniques.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20882278     DOI: 10.1007/s00259-010-1630-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

1.  Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer.

Authors:  Tom R Miller; Edward Pinkus; Farrokh Dehdashti; Perry W Grigsby
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

2.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

3.  Accelerated image reconstruction using ordered subsets of projection data.

Authors:  H M Hudson; R S Larkin
Journal:  IEEE Trans Med Imaging       Date:  1994       Impact factor: 10.048

4.  Exact and approximate rebinning algorithms for 3-D PET data.

Authors:  M Defrise; P E Kinahan; D W Townsend; C Michel; M Sibomana; D F Newport
Journal:  IEEE Trans Med Imaging       Date:  1997-04       Impact factor: 10.048

5.  The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Authors:  L Sokoloff; M Reivich; C Kennedy; M H Des Rosiers; C S Patlak; K D Pettigrew; O Sakurada; M Shinohara
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

6.  Cerenkov luminescence imaging of medical isotopes.

Authors:  Alessandro Ruggiero; Jason P Holland; Jason S Lewis; Jan Grimm
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

7.  Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target.

Authors:  Paolo Farace; Daniela D'Ambrosio; Flavia Merigo; Mirco Galiè; Cristina Nanni; Antonello Spinelli; Stefano Fanti; Anna Degrassi; Andrea Sbarbati; Domenico Rubello; Pasquina Marzola
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-18       Impact factor: 9.236

8.  FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.

Authors:  T Higashi; N Tamaki; T Torizuka; Y Nakamoto; H Sakahara; T Kimura; T Honda; T Inokuma; S Katsushima; G Ohshio; M Imamura; J Konishi
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

9.  Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism.

Authors:  Mirco Galiè; Paolo Farace; Cristina Nanni; Antonello Spinelli; Elena Nicolato; Federico Boschi; Paolo Magnani; Silvia Trespidi; Valentina Ambrosini; Stefano Fanti; Flavia Merigo; Francesco Osculati; Pasquina Marzola; Andrea Sbarbati
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.

Authors:  P Lindholm; H Minn; S Leskinen-Kallio; J Bergman; U Ruotsalainen; H Joensuu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

View more
  29 in total

Review 1.  Functional imaging and endoscopy.

Authors:  Jian-Guo Zhang; Hai-Feng Liu
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

2.  In vivo Cerenkov luminescence imaging: a new tool for molecular imaging.

Authors:  Gregory S Mitchell; Ruby K Gill; David L Boucher; Changqing Li; Simon R Cherry
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

Review 3.  Čerenkov radioactive optical imaging: a promising new strategy.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03       Impact factor: 9.236

4.  Cherenkov radiation fluence estimates in tissue for molecular imaging and therapy applications.

Authors:  Adam K Glaser; Rongxiao Zhang; Jacqueline M Andreozzi; David J Gladstone; Brian W Pogue
Journal:  Phys Med Biol       Date:  2015-08-13       Impact factor: 3.609

Review 5.  Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging.

Authors:  Ryo Tamura; Edwin C Pratt; Jan Grimm
Journal:  Semin Nucl Med       Date:  2018-03-16       Impact factor: 4.446

6.  Fast-specific tomography imaging via Cerenkov emission.

Authors:  Jianghong Zhong; Chenghu Qin; Xin Yang; Zhe Chen; Xiang Yang; Jie Tian
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

7.  Unified approach for bioluminescence, Cerenkov, β, X and γ rays imaging.

Authors:  Antonello E Spinelli; Carmen R Gigliotti; Federico Boschi
Journal:  Biomed Opt Express       Date:  2015-05-21       Impact factor: 3.732

8.  Performance evaluation of endoscopic Cerenkov luminescence imaging system: in vitro and pseudotumor studies.

Authors:  Xin Cao; Xueli Chen; Fei Kang; Yenan Lin; Muhan Liu; Hao Hu; Yongzhan Nie; Kaichun Wu; Jing Wang; Jimin Liang; Jie Tian
Journal:  Biomed Opt Express       Date:  2014-09-17       Impact factor: 3.732

9.  Cerenkov imaging - a new modality for molecular imaging.

Authors:  Daniel Lj Thorek; Robbie Robertson; Wassifa A Bacchus; Jaeseung Hahn; Julie Rothberg; Bradley J Beattie; Jan Grimm
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

10.  Intraoperative imaging of tumors using Cerenkov luminescence endoscopy: a feasibility experimental study.

Authors:  Hongguang Liu; Colin M Carpenter; Han Jiang; Guillem Pratx; Conroy Sun; Michael P Buchin; Sanjiv S Gambhir; Lei Xing; Zhen Cheng
Journal:  J Nucl Med       Date:  2012-08-17       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.